RxDoctor Payments Data

Jessica Bray

Nurse Practitioner · Palmer, AKNPI 1104590751

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Inari Medical, Inc. at 43.3% of the total. Among nurse practitioner clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,190in general payments, 2019–2025

Across 71 payments — averaging $73.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$2K
  • Medtronic$1K
  • Stryker$406
  • Actelion Pharmaceuticals US, Inc.$300
  • E.r. Squibb & Sons, L.L.C.$242
  • Merck$182
  • plus $606 from 8 others

What the payments were for

  • Travel & lodging$2,93156%
  • Food & beverage$2,16042%
  • Education$992%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,190 in reported general payments places this provider in the 95th percentile of 212 nurse practitioner providers in Alaska.

See all nurse practitioner providers in Alaska

Medicare billing

Part B allowed, 2024
$71,057
Medicare patients
270
Services billed
1,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$105,441
EntrestoSacubitril/Valsartan40$53,783
FarxigaDapagliflozin Propanediol32$31,478
Repatha SureclickEvolocumab35$28,863
JardianceEmpagliflozin27$26,515
Praluent PenAlirocumab28$16,893
BrilintaTicagrelor11$9,703
Rosuvastatin Calcium150$3,024
Varenicline Tartrate11$2,113
Metoprolol Succinate117$1,623
Atorvastatin Calcium80$1,179
Losartan Potassium101$1,155
Ezetimibe44$1,124
Carvedilol100$1,026
ClopidogrelClopidogrel Bisulfate60$871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$105,44179 claims
NovartisEntresto$172$53,78340 claims
AstraZenecaFarxiga, Brilinta$150$41,18143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 212 nurse practitioner providers in Alaska.

Other nurse practitioner in Palmer

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →